Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient

NCT06986837 | Completed

• 2 other identifiers: PAP_RNI_2019/082019-A03033-54
• Study Type: observational
• Target: 92
• Locations: 1 country
• Sites: 1

Brief Summary

Sickle cell disease is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis and chronic inflammation. Activated platelets of Sickle cell disease patients participated to both chronic inflammation and painful vaso-occlusive crisis . The main aim of this study is to characterize the contribution of Nucleotide-binding domain Leucine Rich repeat containing Protein 3 inflammasome in platelets' activation in Sickle cell disease and to connect platelet activation, inflammation and sickle cell disease complication.

Conditions

Sickle Cell Disease

Keywords

platelets; NLRP3; HMGB1; BTK

Outcome Measures

Primary Outcomes (1)

• platelets' Nucleotide-binding domain Leucine Rich repeat containing Protein 3 activation

  flow cytometry

  Baseline

Study Arms (3)

Patients SS

Sixty SS patients

Patients SC

Twenty SC patients

Control group AA

Patients without hemoglobin disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with sicke cell disease in a steady state at inclusion

You may qualify if:

• patients with SS or SC Sickle cell disease
• diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
• patient followed up for Sickle cell disease at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)
• patients who will provide written informed consent in accordance with the Declaration of Helsinki
• patients affiliated to national social security

You may not qualify if:

• \- patients with hemoglobinopathy other than SS and SC Sickle cell disease
• patients with a transfusion therapy or on bleeding therapy for less than three months
• patients no affiliated to national social security
• pregnant or breastfeeding patients
• patients who will not provide written informed consent in accordance with the Declaration of Helsinki

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Guadeloupe: lead

Study Sites (1)

Chu de La Guadeloupe

Pointe-à-Pitre, 97159, Guadeloupe

Location

Related Publications (1)

• Koehl B, Claude L, Reminy K, Tarer V, Baccini V, Romana M, Colin-Aronovicz Y, Damaraju VL, Sawyer M, Peyrard T, Etienne-Julan M, Le Van Kim C, Azouzi S, Reininger L. Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait. Br J Haematol. 2023 Mar;200(6):812-820. doi: 10.1111/bjh.18586. Epub 2022 Dec 4.

  PMID: 36464247 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

one blood collection will be realized during the annual follow up visit of the patients and during the screening visit for the controls

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• veronique Baccini, MD PhD

  CHU de la Guadeloupe

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2025
• First Posted: May 23, 2025
• Study Start: October 14, 2020
• Primary Completion: February 5, 2023
• Study Completion: April 20, 2024
• Last Updated: May 23, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

GU (1)